Article Sidebar
Main Article Content
Abstract
Background: Breast cancer is cancer in women with the highest incidence. Adriamycin-cyclophosphamide (AC) chemotherapy is a breast cancer therapy with good efficacy, but its effectiveness has not been maximized. The okra fruit extract is known to have anti-cancer effects from lectins, so it can be used as a complementary chemotherapy therapy to increase effectiveness with minimal side effects.
Methods: This study is an experimental study using female rats Sprague Dawley strain, aged 4 weeks, were induced by DMBA to form mammary adenocarcinoma cells. Divided into groups; control (K): no treatment, treatment 1 (P1): AC chemotherapy (adriamycin 1.5 mg/time and cyclophosphamide 15 mg/time), treatment 2 (P2): okra extract 150 mg/kgBW/day, and treatment 3 (P3): combination of AC and okra extract.
Results: The highest levels of caspase-3 and apoptosis index were found in the P3 group at 39.66±1.78 and 20.93±1.67, respectively. Giving green okra extract to chemotherapy agents can increase the anti-cancer effect by increasing the apoptosis index and caspase-3 levels significantly (p<0.05) compared to other groups.
Conclusion: Okra fruit extract was able to increase the apoptosis response to adriamycin-cyclophosphamide chemotherapy in vivo, as indicated by the high expression of caspase-3 and apoptosis index.
Keywords
Article Details
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
